摘要
目的:观察和评价伊立替康联合5-FU/LV与单用5-FU/LV对结肠癌患者Th1和Th2类细胞因子基因表达水平的影响。方法:采用逆转录聚合酶链反应(RT-PCR)技术,检测结肠癌患者化疗前后外周血单个核细胞(PBMC)Thl和Th2类细胞因子mRNA表达水平。比较伊立替康联合5-FU/LV与单用5-FU/LV化疗对结肠癌患者细胞因子的影响。结果:结肠癌化疗3周期后,IL-6和IL-10阳性表达均较化疗前显著降低(P<0.05);IL-2和IL-12阳性表达均较化疗前显著升高(P<0.05)。伊立替康联合5-FU/LV组较单用5-FU/LV组能更好的降低结肠癌患者的IL-6、IL-10表达,提高IL-2、IL-12的表达(P<0.05)。结论:结肠癌患者细胞免疫受抑,Thl和Th2类细胞因子表达失衡,化疗可使结肠癌患者Th2类细胞因子的强势表达向Thl类逆转。伊立替康合并5-FU/LV能更好的改善患者的免疫状况,有助于机体的预后和康复。
Objective：Through the use of reverse transcription polymerase chain reaction, observe gene expression of Thl and Th2 cytokines in peripheral blood of the patients with colon carcinoma treated with irinotecan combined with 5-FU/LV. Methods：The gene expression of Thl and Th2 cytokines before and after chemotherapy in colon carcinoma was detected by reverse transcription polymerase chain reaction （RT-PCR）. Results. The level of IL-6 and IL-10 of colon cancer patient reduced after chemotherapy （P 〈 0. 05 ） ;the level of IL-2 and IL-12 of colon cancer patient rise after chemotheraey （ P 〈 0. 05 ）. Irinotecan combined with 5-FU/LV group reduce the level of IL-6, IL-10 and rise the level of IL-2, IL-12 more effective than 5-FU/LV group only （P 〈0. 05）. Conclusion：The colon carcinoma patient have cell immune deficiency irinotecan combined with 5-FU/LV can improve the immunity state of colon cancer patient.
出处
《临床肿瘤学杂志》
CAS
2007年第4期267-270,共4页
Chinese Clinical Oncology
基金
山东省卫生厅课题资助项目(2001CA1DCB4)
